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The role of adrenomedullin and receptors in glomerular hyper-
filtration in streptozotocin-induced diabetic rats.
Background. Since adrenomedullin (AM) elicits vasodi-
latation by binding to specific AM receptors consisted
of calcitonin-receptor-like receptor (CRLR)/receptor-activity-
modifying protein 2 (RAMP2) or CRLR/receptor-activity-
modifying protein 3 (RAMP3) on endothelial cells and stimulat-
ing nitric oxide production, AM possibly involves in glomerular
capillary dilatation in early phase of diabetic nephropathy.
Methods. Streptozotocin (STZ)-induced diabetic Sprague-
Dawley rats at 4 weeks after the injection were employed for
expression studies of AM, RAPM2, and RAMP3. The measure-
ment of AM peptide levels in kidney tissue, plasma, and urine
was performed. Human aortic endothelial cells (HAEC) were
used to investigate functional link between glucose-induced
AM production and nitric oxide release.
Results. STZ rats showed glomerular hypertrophy and in-
creased urinary NO2− and NO3− excretion. By Northern blot
analyses, AM and RAPM2 mRNAs significantly increased in
the kidneys of STZ rats, while RAMP3 mRNA was not al-
tered. In STZ rats, AM peptide was actively secreted into urine
(1280 ± 360 fmol/day vs. control 110 ± 36 fmol/day). AM pep-
tide was mainly detected on cortical and medullary collecting
duct cells in control rat kidneys and AM peptide and mRNA
were up-regulated on afferent arterioles and glomeruli of STZ
rats. RAMP2 expression was detected on afferent arterioles
and not in glomeruli in control rats and it was up-regulated
on glomerular endothelial cells in STZ rats. In HAEC culture,
D-glucose stimulated AM and nitric oxide production and they
were suppressed by addition of AM antisense oligodeoxynu-
cleotides.
Conclusion. Up-regulated expression of AM and RAMP2
in afferent arterioles and glomeruli may be related to selec-
tive dilatation of glomerular capillary in acute phase of type 1
diabetes.
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tric oxide, glomerular hypertrophy, vasodilatation, hyperfiltration,
adrenomedullin.
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In type 1 and type 2 diabetes mellitus, persistent hyper-
glycemia induces progressive and irreversible glomeru-
losclerosis that ultimately results in end-stage renal fail-
ure. Intracellular signaling events [1, 2] and advanced gly-
cation end products (AGEs) [3] are critically involved
in accumulation of extracellular matrix glycoproteins. In
addition to such cellular events, acute intrarenal hemody-
namic alterations in response to hyperglycemia are char-
acteristic feature of acute phase of diabetic nephropathy
in type 1 diabetes (i.e., increased glomerular capillary vol-
ume and selective dilatation of afferent arterioles). The
subsequent glomerular hyperfiltration is believed to be
the critical event that leads to the following progressive
renal injury [4]. Many vasoactive substances were postu-
lated to involve in this process, such as atrial natriuretic
peptide (ANP) [5, 6], nitric oxide [7], and thromboxane
A2 [8]; however the precise molecular mechanisms of
glomerular hypertrophy and hyperfiltration still remain
unknown.
To investigate the underlying molecular mechanisms
in glomerular hyperfiltration and hypertrophy, we have
been studying the gene expression profile by genomics
approaches, such as polymerase chain reaction (PCR)-
based subtractive library screening and cDNA arrays,
using streptozotocin (STZ)-induced diabetic [9–13] and
partially ablated mice kidneys [14, 15]. In such efforts,
we have found that adrenomedullin (AM) mRNA was
expressed in normal kidneys and up-regulated in STZ-
induced diabetic Cr: CD-1 (ICR) BR mouse kidneys
[10]. AM is a potent vasorelaxant peptide of 52 amino
acid residues originally isolated from human pheochro-
mocytoma tissue [16]. It has been demonstrated that en-
dothelial cells and vascular smooth muscle cells (VSMC)
actively synthesize and secrete AM peptide and their
transcriptional activities are 20 and 4 times higher than
that of adrenal glands, respectively [17]. It has been re-
ported that a receptor with seven transmembrane do-
mains, the calcitonin-receptor-like receptor (CRLR), can
function as an AM receptor, depending on the association
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with receptor-activity-modifying protein 2 or 3 (RAMP2
or RAPM3) [18, 19]. AM derived from both endothelin
cells and VSMC elicits the hypotensive effects through
binding to AM receptors on endothelin cells, increase in
intracellular cyclic guanosine monophosphate (cGMP),
and release of nitric oxide [20].
In STZ-induced diabetic Sprague-Dawley rats, we
demonstrated that endothelial cell nitric oxide synthase
(ecNOS) selectively up-regulates in afferent arterioles
and glomerular endothelial cells, enhances nitric oxide
synthesis, and causes preferential dilatation of afferent
arterioles and glomerular capillaries [21]. In addition,
it was reported that hyperglycemia increases the vascu-
lar expression of AM through protein kinase C (PKC)-
dependent pathway [22]. In line of evidences, we hypoth-
esize that up-regulated AM and its receptors in glomeruli
induce the expression of ecNOS and release of nitric ox-
ide by which glomerular capillaries would be dilated. In
this study, we demonstrated the localization of AM and its
receptors and alterations of metabolism of AM in STZ-
induced diabetic Sprague-Dawley rats. We also demon-
strate the functional link between high glucose–induced
expression of AM and release of nitric oxide from cul-
tured human endothelial cells.
METHODS
Animals
Male Sprague-Dawley rats were purchased from
Charles River Japan (Yokohama, Japan). Diabetes was
induced by the intravenous injection of 65 mg/kg body
weight STZ (Sigma Chemical Co., St. Louis, MO, USA)
in citrate buffer, pH 4.5. After 24 hours, hyperglycemia
more than 15 mmol/L was confirmed and divided into two
groups: (1) STZ-induced diabetes group (N = 10) and
(2) insulin-treated group (N = 10). In the insulin-treated
group, NPH insulin with dosage of 10 to 40 units/animal
was injected in order to obtain fasting glucose levels of
80 to 150 mg/dL. Control Sprague-Dawley rats (N = 10)
were injected with citrate buffer only. All rats were sacri-
ficed at 4 weeks after the injection and plasma, urine, and
kidneys tissues were subjected to following studies. For
AM mRNA and AM peptide isolation, the kidney cortex
was excised and used.
Northern blot analysis
Two micrograms poly (A)+ RNAs isolated from cortex
of kidney tissues were subjected to 2.2 mol/L formalde-
hyde 1% agarose gel electrophoresis and capillary trans-
ferred to the Hybond N+ nylon membranes (Amersham,
Arlington Heights, IL, USA). The membranes were
hybridized with [a-32P] deoxycytidimine triphosphate
(dCTP)-radiolabeled rat AM, RAMP2, RAMP3, and
gycleraldehyde-3-phosphate dehydrogenase (GAPDH)
(1 × 106 cpm/mL) cDNAs at 68◦C in ExpressHybTM Hy-
bridization Solution (Clontech, Palo Alto, CA, USA) for
2 hours. Filters were washed at high stringency conditions
[i.e., four times in 1 × standard sodium citrate (SSC)/0.1%
sodium dodecyl sulfate (SDS) at 24◦C, followed by two
times at 68◦C in 0.1 × SSC/0.1% SDS. Autoradiography
was prepared using Bio-Imaging Analyzer System (BAS-
1800 II, FujiFilm, Tokyo, Japan).
In situ hybridization studies
The kidneys of Sprague-Dawley rats were har-
vested after intracardiac catheter perfusion with 4%
paraformaldehyde in phosphate-buffered saline (PBS),
and fixed at 4◦C for 3 hours and dehydrated in
ethanol. Tissues were embedded in paraffin; 4 lm thick
sections were prepared and mounted on RNase-free
ProbeOn Plus glass slides (Fisher Scientific, Pittsburgh,
PA, USA). Oligodeoxynucletide (ODN) of AM (5′-
CCAGCTTCATTCTGTAGCGATGCTCCG-3′) linked
to a 3′ biotinylated tail [3′-(TAG)5-BBB-(TAG)2-BBB-
5′] were synthesized and used as an antisense probe
(Research Genetics, Huntsville, AL, USA). Biotinylated
polyT and polyA probes were used as a positive and
negative control, respectively. In situ hybridization was
performed using MicroProbeTM System (Fisher Scien-
tific) and In Situ Sampler Kit (Research Genetics) fol-
lowing the manufacturer’s protocol. In brief, the tissue
sections were rapidly dewaxed (AutoDewaxer), cleared
with alcohol (AutoAlcohol), and rehydrated with a Tris-
based buffer, pH 7.4 (Universal Buffer). The tissue
sections were digested with a stable pepsin solution
(0.5 mg/dL) for 3 minutes. The probes (1 lg/mL) were
applied to the tissues and incubated at 45◦C for 30
minutes. Finally, the biotin-labeled hybrids were de-
tected by horseradish peroxidase-linked streptavidin and
diaminobenzidine and the slides were counterstained
with hematoxylin and cover slipped with Clear Mount
(Research Genetics).
Immunohistochemistry
Immunolocalization of AM, RAMP2, and RAMP3
were assessed by immunoperoxidase ABC kit (Vec-
tor Lab, Burlingame, CA, USA), as described previ-
ously [21]. Briefly, formalin-fixed paraffin sections (4 lm)
were dewaxed, cleared, and rehydrated. The sections
were first incubated for 60 minutes with rabbit anti-AM
serum (Peninsula Laboratories, San Carlos, CA, USA)
or goat anti-RAMP2 and anti-RAMP3 polyclonal serum
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
The sections were then incubated with biotinylated horse
antirabbit and antigoat IgG for 30 minutes at 22◦C,
respectively, and followed by treatment with 3,3-diamino-
benzidine and hydrogen peroxide. Immunofluorescence
for ecNOS and inducible NOS (iNOS) using polyclonal
rabbit antirat ecNOS and antirat iNOS (Calbiochem, San
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Diego, CA, USA) was performed as previously described
[21, 23].
NO2−/NO3−
Urine samples and culture media were assayed for the
stable nitric oxide metabolic end products, NO2− and
NO3− with a Nitrate/Nitrite Assay Kit (Cayman Chemi-
cal, Ann Arbor, MI, USA).
RIA assay for plasma, urine, and kidney tissue AM
Plasma and urine AM levels were measured by the
radioimmunoassay (RIA) system using antiserum #172-
CI-7 against human AM (40–52) reported previously [24].
Plasma and urine samples were kept in −20◦C in the pres-
ence of 0.1% ethylenediaminetetraacetic acid (EDTA)/2
Na and Trasylol (500 unit/mL). N-Tyr derivative of hu-
man AM(40–52) was radioiodinated by the lactoperoxi-
dase method, and its N-Tyr-monoiodinated form, isolated
by reverse-phase high performance liquid chromatogra-
phy (HPLC), was used as a tracer. For the quantifica-
tion of AM in renal tissues, kidneys were minced and
boiled for 10 minutes in 10 volumes of water. Acetic
acid was added to a final concentration of 1 mol/L. The
boiled tissues were homogenized using a polytron ho-
mogenizer, transferred to polypropylene test tubes, and
centrifuged. The resulting supernatants were condensed
with Sep-pak C18 cartridges and subjected to RIA for AM
measurement [25].
Antisense experiments using human
aortic endothelial cell culture
Human aortic endothelial cells (HAECs) isolated from
thoracic aorta were purchased from Kurabo (Osaka,
Japan). HAECs were maintained in HuMedia-EB2
medium (Kurabo) in the presence of 2% fetal bovine
serum (FBS), 100 mg/dL D-glucose, 10 ng/mL human
epithelial growth factor (hEGF), 1 lg/mL hydrocorti-
sone, 5 ng/mL human fibroblast growth factor (hFGF),
10 lg/mL heparin, 50 lg/mL gentamicin, and 50 ng/mL
amphotericin B. The cells at six to eight passage were
used for all experiments and HAECs were grown to
confluence in a 6-well plate. After 12-hour preincubation
in HuMedia-EB2 medium containing 0.1% FBS, HAECs
were incubated with HuMedia-EB2 medium containing
100 mg/dL D-glucose, 450 mg/dL D-glucose, and 450
mg/dL L-glucose. Nonsense phosphorothioated ODN,
5′-GATCGATCGATCGATCGATCGATCGATC-3′;
antisense ODN of human AM, 5′-CCTGCTAAGAGAG
TGATCTGCCAAGTAC-3′; and sense ODN of human
AM, 5′-GTACTTGGCAGATCACTCTCTTAGCAGG-
3′ synthesized and purified by HPLC and were added into
culture media at concentration of 0.1 lmol/L. Culture
media were collected after 12 hours and subjected to
RIA assay for AM and measurement of NO2− and NO3−
with a Nitrate/Nitrite Assay Kit.
Statistical analysis
Data are expressed as the mean ± SEM and analyzed
by the unpaired Student t test, or by a one-way analysis of
variance (ANOVA) by Fisher t test when multiple com-
parisons against the control were required. P < 0.01 was
regarded as statistically significant.
RESULTS
Glomerular hyperfiltration and renal hypertrophy
in STZ-induced diabetic rats
In STZ rats, sustained hyperglycemia was observed
throughout 4 weeks of experimental period and plasma
glucose (38.2 ± 0.8 mmol/L) and fructosamine (223 ±
6 lmol/L) levels significantly increased compared with
control group, 12.0 ± 0.6 mmol/L and 141 ± 13 lmol/L,
respectively (Fig. 1A and 1B). The body weight was sig-
nificantly lower in STZ rats (217 ± 91 g) compared with
control rats (300 ± 8 g), while the kidney/body weight
ratio (1.38 ± 0.18%) (Fig. 1C), urine volume (102 ±
12.3 mL/day) (Fig. 1D), and creatinine clearance (980 ±
118 lL/min/100g) (Fig. 1E) significantly increased in STZ
group compared with control rats, 0.82 ± 0.04%, 20.1 ±
2.3 mL/day, and 480 ± 98 lL/min/100g, respectively.
Urinary excretion of NO2− + NO3− and expression
of ecNOS in renal tissues
Urinary excretion of NO2−+ NO3− prominently in-
creased in STZ group (2580 ± 780 nmol/day) com-
pared with control rats (1240 ± 242 nmol/day). Insulin
treatment lowered the plasma glucose and fructosamine
levels and also ameliorated hypertrophy of the kid-
neys, glomerular hyperfiltraion, and urinary excretion of
NO2− + NO3− (Fig. 1F).
For investigation of nitric oxide production sites, im-
munofluorescence study for ecNOS and iNOS was per-
formed using kidney tissues. The glomeruli of the control
rats showed faint staining for ecNOS (Fig. 2A). In STZ
rats, the afferent arterioles and the glomeruli revealed
the enhanced immunoreactivity of ecNOS compared with
control rats (Fig. 2C). Insulin treatment attenuated intra-
glomerular expression of ecNOS (Fig. 2B). In contrast,
no immunoreactivity for iNOS was seen in both STZ and
control rat kidneys.
Northern blot analyses of AM mRNA and
the measurement of plasma, urinary, and
tissue concentration of AM peptide
Northern blot analyses revealed that single mRNA
transcripts of both AM and RAMP2 increased in STZ
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Fig. 1. Glucose metabolism, renal functions, urinary excretion of nitric oxide metabolic end products, and adrenomedullin (AM) concentrations
of plasma, urine, and kidney tissues in control, streptozotocin (STZ)-induced diabetic, and STZ-induced diabetic Srague-Dawley rats treated with
human insulin (INS) (A to I). Plasma, urine, and tissue AM levels were measured by the radioimmunoassay (RIA) system using antiserum #172-
CI-7 against human AM(40–52) reported previously [24]. The stable nitric oxide metabolic end products, NO2 and NO3, were measured with a
Nitrate/Nitrite Assay Kit (Cayman Chemical, Ann Arbor, Mi, USA). Data are shown by mean ± SEM. ∗P < 0.01; ∗∗P < 0.001; ∗∗∗P < 0.001.
rats compared with control rats. In contrast, mRNA ex-
pression of RAPM3 was lower than AM and RAMP2
mRNAs and the up-regulation of RAMP3 by the induc-
tion of diabetes was also minimal. Insulin treatment par-
tially reduced mRNA expression of AM and RAMP2. We
re-probed the membranes with GAPDH and confirmed
that the amount and quality of loaded mRNA was similar
in each group (Fig. 3).
Plasma AM concentrations significantly decreased in
STZ rats (0.98 ± 0.48 fmol/mL) compared with con-
trol rats (1.78 ± 0.68 fmol/mL) (Fig. 1G); however, vast
amount of AM was actively secreted into urine of STZ
rats (1280 ± 360 fmol/day), while AM was normally se-
creted at the levels of 110 ± 36 fmol/day in control rats
(Fig. 1H). Measurement of AM content in kidney tis-
sues revealed no significant differences between control
and STZ rats, 410 ± 89 and 390 ± 86 fmol/kidney, re-
spectively (Fig. 1I). The data suggested that AM was ac-
tively transcribed and translated in the kidney tissues and
most of them were immediately secreted into urine and
the circulatory plasma AM was reduced by glomerular
hyperfiltration.
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Fig. 2. Immunofluorescence staining of endothelial cell nitric oxide
synthase (ecNOS). The glomeruli of control Sprague-Dawley rats
(CON) show faint staining for ecNOS (A). In streptozotocin (STZ)-
induced diabetic Sprague-Dawley rats, the afferent arterioles and the
glomeruli reveal the enhanced immunoreactivity of ecNOS compared
with control rats (C). Insulin treatment (INS) attenuates intraglomeru-
lar expression of ecNOS compared with STZ rats (B) (bar = 50 lm).
Localization of AM mRNA and AM peptide
To investigate the production sites of AM in renal
tissues, in situ hybridization and immunohistochemical
studies were performed. In control rats, mRNA signals
of AM were not detected on glomerular cells (Fig. 4A).
In STZ rats, mRNA signals of AM were readily detected
on glomerular cells and mRNA expression seemed to be
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Fig. 3. Northern blot analyses of adrenomedullin (AM) and its re-
ceptor, receptor-activity-modifying proteins 2 and 3 (RAMP2 and
RAMP3). Two micrograms poly (A)+ RNAs isolated from kidneys
were subjected to 2.2 mol/L formaldehyde 1% agarose gel electrophore-
sis and capillary transferred to nylon membranes. The membranes
were hybridized with [a-32P] deoxycytidimine triphosphate (dCTP)-
radiolabeled adrenomedullin, RAMP2, and RAMP3 cDNAs. The
membrane was reprobed with glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (1 × 106 cpm/mL) and indicated in lower panel. Single
mRNA transcripts of both AM and RAMP2 increase in streptozotocin
(STZ)-induced diabetic rats compared with control rats, while expres-
sion of RAMP3 is similar to control. Insulin treatment (INS) partially
reduces mRNA expression of AM and RAMP2. The densitometric ra-
tios of adrenomedullin, RAMP2 and RAMP3 to GPDH are analyzed
(N = 10) and indicated in lower panel. Data are shown by mean ± SEM.
∗P < 0.01.
enhanced in the glomeruli (Fig. 4C). By treatment of in-
sulin, glomerular mRNA expression of AM was reduced
(Fig. 4B). In contrast, AM peptide was not detected in
glomeruli in control rats and the immunoreactivities were
mainly seen in cytoplasm of cortical and medullary col-
lecting duct cells and cortical distal tubules (Fig. 5A and
B). Small arteries and arterioles also did not show ap-
parent immunoractivities for AM peptide (Fig. 5B and
C). In STZ rats, AM was up-regulated in small arter-
ies, afferent arterioles, and in glomerular cells. In small
arteries, AM staining was especially up-regulated on
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Fig. 4. In situ hybridization of adrenomedullin (AM) mRNA.
Oligodeoxynucletide (ODN) of AM (5′-CCAGCTTCATTCTGTAG
CGATGCTCCG-3′) linked to a 3′ biotinylated tail [3′-(TAG)5-BBB-
(TAG)2-BBB-5′] were synthesized and used as antisense probe. The
biotin-labeled hybrids were detected by horseradish peroxidase-linked
streptavidin and diaminobenzidine. In control (CON) rats, mRNA sig-
nals of AM are faintly detected on glomerular cells (A), while signals are
not observed in renal interstitium. In streptozotocin (STZ) rats, mRNA
signals of AM are readily detected on glomerular cells and mRNA ex-
pression seemed to be enhanced in the glomeruli (C). By treatment of
insulin, glomerular mRNA expression of AM is ameliorated (B). Poly
A probe dose not show any signals on glomerulus (D).
endothelial cells (Fig. 5D). In glomeruli, endothelial cells,
podocytes and Bowman’s epithelial cells showed promi-
nent immunoreactivities (Fig. 5E and F). In afferent ar-
terioles, both smooth muscle cells and endothelial cells
showed AM staining (Fig. 5G and H). Taken together,
actively synthesized AM is not stored but constitutively
secreted from glomerular endothelial cells in normal kid-
neys. In contrast, the transcriptional activity of AM is
lower in the tubular epithelial cells but AM peptide is
stored in the cytoplasm. Since plasma AM concentra-
tion was reduced and vast amount of AM was secreted
into urine, most of secreted AM from both systemic
vascular endothelial cells and glomerular cells was fil-
tered into the urine space of glomeruli under the con-
dition of glomerular hyperfiltration in hyperglycemic
states.
Immunolocalization of RAMP2 and RAMP3
To investigate localization of AM-receptor com-
plexes, RAMP2/CRLR and RAPM3/CRLR, immunohis-
tochemistry was performed using specific antibody raised
against RAMP2 and RAMP3. RAMP2 was expressed on
smooth muscle and endothelial cells of interlobular arter-
Fig. 5. Immunolocalization of adrenomedullin (AM) peptide in con-
trol (CON) and streptozotocin (STZ)-induced diabetic kidneys. AM
peptide is not detected in glomeruli in control rats and the immunoreac-
tivities are mainly seen in cytoplasm of cortical (A and B) and medullary
collecting duct cells. Small arteries and arterioles also do not show ap-
parent immunoreactivities for AM peptide (C). In STZ rats, AM stain-
ing in small arteries, afferent arterioles, and in glomerular cells, and
AM staining especially up-regulated on endothelial cells (En) of small
arteries (D). In glomeruli, endothelial cells (En), podocytes (Pod) and
Bowman’s epithelial cells (Epi) show prominent immunoreactivities (E
and F). In afferent arterioles, both smooth muscle cells and endothelial
cells show AM staining (G and H, arrows) [bar = 100 lm in (A), 50 lm
in (B to E and G), 10 lm in (F), and 25 lm in (H)].
ies and afferent arterioles in normal kidney tissues. Im-
munoreactivities were not seen on glomerular cells or on
tubular cells (Fig. 6A and B). In STZ rats, the expression
of RAMP2 was up-regulated in glomeruli, glomerular en-
dothelial cells and mesangial cells (Fig. 6C). In afferent ar-
terioles, RAMP2 was prominently expressed on smooth
muscle cells and endothelial cells (Fig. 6D) while expres-
sion was less in efferent arterioles (Fig. 6E). In addition to
glomeruli, immunoreactivities were up-regulated in col-
lecting duct tubules (Fig. 6F). RAMP3 was mainly ex-
pressed in collecting duct cells in control kidneys (Fig. 6G)
and the altered expression was not observed in STZ kid-
neys (Fig. 6H).
546 Hiragushi et al: Adrenomedullin in diabetic nephropathy
Fig. 6. Immunolocalization of receptor-
activity-modifying proteins 2 and 3 (RAMP2
and RAMP3). RAMP2 is expressed on
smooth muscle and endothelial cells of
interlobular arteries and afferent arterioles
(Af) in control kidney tissues (CON)(A
and B). Immunoreactivities are not seen
on glomerular cells or on tubular cells. In
streptozptocin (STZ)-induced diabetic rats,
the expression of RAMP2 is up-regulated
in glomeruli, mesangial cells, glomerular
endothelial cells, and epithelial cells (C). In
afferent arterioles (Af), RAMP2 is promi-
nently expressed on smooth muscle cells and
endothelial cells (D), while expression is less
impressive in efferent arterioles (Ef) (E). In
addition to glomeruli, immunoreactivities
are up-regulated in collecting duct tubules
(c) (F) and almost comparable with small
arteries (A) (F). RAMP3 is mainly expressed
in collecting duct cells in control kidneys (G)
and the altered expression is not observed in
STZ kidneys (H).
Antisense experiments using HAEC culture
To investigate the relation between AM secretion
and nitric oxide production form endothelial cells, an-
tisense experiments using HAEC culture system were
performed. Under the presence of 100 mg/dL D-glucose,
AM was produced at a rate of 5.83 ± 0.25 fmol/105
cells·12 hours into culture media. The production of AM
was significantly increased under the presence of 450
mg/dL D-glucose (7.82 ± 0.83 fmol/105 cells,·12 hours),
and the secretion of AM was not altered by addition
of 450 mg/dL L-glucose (6.24 ± 0.45 fmol/105 cells,·12
hours). At 100 mg/dL glucose, the addition of 0.1 lmol/L
nonsense ODN (5.46 ± 0.36 fmol/105 cells,·12 hours,
P = 0.2987) and 0.1 lmol/L AM sense ODN (5.82 ±
0.30 fmol/105 cells,·12 hours, P = 0.0592) did not reveal
significant inhibitory effects on AM release. Similarly, at
450 mg/dL glucose, 0.1 lmol/L nonsense ODN (7.68 ±
0.36 fmol/105 cells,·12 hours) and 0.1 lmol/L AM sense
ODN (7.24 ± 0.25 fmol/105 cells,·12 hours) did not re-
vealed the suppression of AM production. The addition
of 0.1 AM lmol/L antisense ODN inhibited the AM re-
lease compared with nonsense and AM sense treated con-
trol HAECs under both normal (3.06 ± 0.44 fmol/105
cells,·12 hours) and high glucose (3.78 ± 0.22 fmol/105
cells,·12 hours) concentrations (Fig. 7A).
The release of NO2− and NO3− into culture me-
dia was also examined by a Nitrate/Nitrite Assay Kit.
NO2− and NO3− were significantly increased under the
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Fig. 7. Antisense experiments using human
aortic endothelial cell (HAEC) culture. After
12-hour preincubation in HuMedia-EB2
medium containing 0.1% fetal bovine serum
(FBS) without D-glucose, HAECs were
incubated with HuMedia-EB2 medium con-
taining 100 mg/dL D-glucose and 450 mg/dL
D-glucose. Nonsense phosphorothioated
oligonucletotides (ODN), 5′-GATCGATC
GATCGATCGATCGATCGATC-3′; antise-
nse ODN of human adrenomedullin (AM), 5′-
CCTGCTAAGAGAGTGATCTGCCAAG
TAC-3′; and sense ODN of human AM, 5′-
GTACTTGGCAGATCACTCTCTTAGCA
GG-3′ were included into culture media at
concentration of 0.1 lmol/L. Supernatants
were collected after 12 hours incubation
and AM levels were measured by the
radioimmunoassay (RIA)system using anti-
serum #172-CI-7 against human AM(40–52)
reported previously [24]. The stable nitric
oxide metabolic end products, NO2 and NO3,
were measured with a Nitrate/Nitrite Assay
Kit (Cayman Chemical, Ann Arbor, MI,
USA). Data are N = 6 and shown by mean ±
SEM. ∗P < 0.01.
presence of 450 mg/dL D-glucose (25.3 ± 0.81 nmol/105
cells,·12 hours) compared with 100 mg/dL D-glucose (15.2
± 0.75 nmol/105 cells,·12 hours) and 450 mg/dL L-glucose
(13.2 ± 1.04 nmol/105 cells,·12 hours). The addition of
0.1 lmol/L nonsense and AM sense ODNs did not reveal
the inhibitory effects on NO2− and NO3− release at both
100 and 450 mg/dL glucose levels. Under normal glucose
levels, both AM antisense ODN did not significantly sup-
press NO2− and NO3− release. At 450 mg/dL glucose, the
addition of AM antisense ODN (15.4 ± 1.49 nmol/105
cells,·12 hours) showed on NO2− and NO3− release com-
pared with nonsense AM sense ODNs treated controls
(26.9 ± 1.15 and 24.5 ± 1.12 nmol/105 cells,·12 hours)
(Fig. 7B). The reduction of NO2− and NO3− release by
AM antisense ODNs was prominent under high glucose
conditions compared with normal glucose conditions.
DISCUSSION
Plasma AM levels increased in various pathologic con-
ditions, such as essential hypertension [26, 27], conges-
tive heart failure [28, 29], acute myocardial infarction
[30], chronic renal failure [26, 28], liver cirrhosis [28],
and sepsis [31]. The elevation of plasma AM levels ac-
centuates in a manner parallel with the severity of these
diseases. The increase in plasma AM was more promi-
nent in renal failure than in hypertension. Renal failure
patients with plasma creatinine of 1.5 to 3, 3 to 6, and >6
mg/dL had higher plasma AM levels than healthy sub-
jects by 78%, 131%, and 214%, respectively [26]. In di-
abetes mellitus, plasma AM levels were first reported to
be elevated in a small group of poorly controlled patients
without renal failure [32]. The main production site of
AM in vivo was thought to be the vasculature and the
authors postulated that the rise in plasma AM was due
to a hyperglycemia-induced increase in the blood vessels
since they found high glucose up-regulated AM mRNA
expression in cultured VSMC through PKC-dependent
pathway [22]. However, the evaluation of plasma AM
levels in a larger number of type 1 and type 2 diabetes pa-
tients in later clinical studies yielded conflicting results,
normal [33, 34] or elevated [35, 36] concentrations and
it is now generally accepted that plasma AM concentra-
tions are not directly linked to poor metabolic control and
positively correlated to rather oxidative stress[37], acute
hyperinsulinemia in type 2 diabetes[38], and progression
of microangiopathy, or other risk factors that can cause
endothelial injury [34].
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Generalized vasodilatation is observed in type 1 dia-
betes and the vasodilatation is more evident in the affer-
ent arterioles, and it is believed to lead to capillary hy-
pertension, thus contributing the development of diabetic
microangiopathy [39]. It was reported that AM is able to
induce relaxation in isolated canine retinal arteries [40]
and to increase the diameter of both afferent and efferent
arterioles determined with a videoanalyser using ureter-
ligated hydronephrotic rat kidneys, where no glomerular
filtration was present [41]. Although plasma AM concen-
tration is not directly related to plasma glucose levels re-
ported in recent publications, the evidence that vascular
AM mRNA induced by hyperglycemia both in vivo and
in vitro suggests [22] that locally produced AM may act as
a local factor and exert vasodilatation action in type 1 dia-
betes even if the plasma levels of AM are not increased. In
STZ-induced diabetic Sprague-Dawley rats, we demon-
strated that ecNOS selectively up-regulates in afferent
arterioles and glomerular endothelial cells, enhances ni-
tric oxide synthesis, and causes preferential dilatation of
afferent arterioles and glomerular capillaries in former
studies [21]. Thus, it is quite reasonable to hypothesize
that AM may also elicit vasodilatation action on afferent
arterioles and glomerular capillaries in an autocrine and
paracrine fashion. Another player for the production of
nitric oxide is iNOS and Cosenzi et al [42] recently re-
ported that iNOS levels steadily increased and lead to
increased urine excretion of NO2− and NO3−. We al-
ready reported that iNOS expression gradually increased
in STZ-induced diabetic rats during 50 weeks after the in-
jection of STZ. However, in early phase, 4 weeks after the
induction of diabetes, we investigated both immunostain-
ing and reverse transcription-polymerase chain reaction
(RT-PCR) and we did not detect the expression of iNOS
[23]. Thus, we concluded that ecNOS is mainly respon-
sible for the increased urinary excretion of NO2− and
NO3− in early phase of diabetic glomerular hyperfiltra-
tion.
AM immunoreactivities and gene expressions are
widely distributed in mammalian tissues, including kid-
ney. Immunoreactivities were seen in glomeruli, cortical
distal tubules, and medullary collecting duct cells [43].
In the glomeruli, AM was present both in microvascular
areas and mesangial cells [44]. mRNA expression of AM
was also examined and detected in the glomeruli, cortical
collecting duct cells, inner and outer collecting duct cells
using the RT-PCR technique [45]. In situ hybridization
also revealed AM mRNA expression in the glomeruli
and cortical tubules [46]. Kidney is major source of AM
and expresses AM receptors. AM specific receptors are
composed of CRLR/RAMP2 or CRLR/RAMP3, and
RAMP2 mRNA expression was up-regulated in obstruc-
tive nephropathy [47] and down-regulated renal mass ab-
lation [48] revealed by Northern blot analyses and com-
petitive RT-PCR, respectively. Such observations suggest
that AM and AM receptors have important roles in both
normal and pathologic conditions in the kidney. In normal
renal physiology, AM is a potent vasodilator and indeed
induces a concentration-dependent vasodilatation in the
rat isolated perfused kidney [49]. AM is also a new na-
triuretic peptide and intrarenal infusion of AM resulted
in marked diuretic and natriuretic responses associated
with an increase in glomerular filtration rate and a de-
crease in distal tubular sodium reabsorption [43]. AM
also inhibited platelet-derived growth factor (PDGF) [50]
or endothelin-1 [51] and induced mitogen-activated pro-
tein kinase (MAPK) activation and the proliferation of
mesangial cells.
In STZ-induced diabetic Sprague-Dawley rats, dy-
namic metabolism of AM in the kidney was demonstrated
in this study. AM mRNA was up-regulated in the corti-
cal kidney revealed by Northern blot analyses and AM
mRNA was especially augmented in glomeruli shown by
in situ hybridization. Relatively intense staining of AM
peptide in collecting duct cells in cortex and medulla
compared with glomeruli in both control and diabetic rat
kidneys suggested that glomerular endothelial cells con-
stitutively synthesize and immediately secrete AM and,
in contrast, collecting duct tubular cells store the AM
peptides in the secretion granules in the cytoplasm. Ac-
tually, AM peptide amounts in the cortical kidneys re-
flecting the intracellular storage of AM did not changed
in normal and diabetic kidneys. The discrepancy of vast
amount of urinary secretion of AM and reduced plasma
levels of AM in STZ-induced diabetic rats observed in
this study may be explained by prominent glomerular
hyperfiltration. In vitro culture studies revealed that the
secretion of AM into culture media is enhanced under
high glucose conditions and mRNA expression is accen-
tuated in glomeruli in STZ-induced diabetic rats. In clin-
ical studies with type 1 diabetes patients, plasma AM lev-
els were negatively correlated with creatinine clearance
[35]. Taken together, up-regulated and secreted AM from
glomeruli induces the dilation of glomerular capillaries
and glomerular hyperfiltration, and AM is immediately
filtered into urinary space. In fact, blood pressure of STZ-
induced diabetic rats were not lower compared with con-
trol rats as previously shown [21]. The augmented pro-
tein expression of RAMP2 in glomerular endothelial and
mesangial cell strongly supports this notion. Since uri-
nary excretion of NO2− and NO3− was increased and
ecNOS was selectively up-regulated in afferent arteri-
oles and glomeruli, autocrine, and paracrine regulation
mediated by AM and CRLR/RAMP2 seems to induce
the up-regulation of ecNOS and dilatation of glomerular
capillaries.
We also demonstrated functional link between glucose
induced AM production and nitric oxide release from cul-
tured HAEC. In HAEC culture, inclusion of 450 mg/dL
D-glucose increased both AM and nitric oxide release
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into culture media. Antisense ODN for AM suppressed
both AM concentration and nitric oxide release into cul-
ture media especially under the presence of 450 mg/dL
D-glucose. In HAEC culture, AM release was stimulated
by the addition of 450 mg/dL D-glucose; however, in-
creased production of AM was not comparable to the
degree of enhanced production in STZ-induced diabetic
rat glomeruli in vivo. Since produced AM from affer-
ent arterioles and glomeruli is actively filtered into the
urinary space and the dilatation of afferent arterioles is
prominent compared with efferent arterioles, glomeru-
lar hypertension or augmented shear stress would take
place. In promoter regions of both AM and ecNOS genes,
shear stress responsive element (SSRE) do exist [52, 53]
and their expression would be further up-regulated by
shear stress in vivo. We preliminary checked expression
of ecNOS in HAEC culture, we did not see difference
both Northern blot analysis and Western blot analysis
in 12 hours after exposure to high glucose. In extended
culture for 24 to 48 hours, ecNOS expression increased;
however, HAEC showed endothelial cell dysfunction or
apoptosis and secretion of AM production rather de-
creased. In addition, Hink et al [54] revealed that per-
sistent hyperglycemia induced increase in ecNOS, which
can lead to increase in oxidant stress and decrease in ni-
tric oxide bioavailability via an uncoupling mechanism.
Thus, we measured AM concentration and nitric oxide in
12 hours culture to investigate the glucose-induced AM
and nitric oxide production, where ecNOS expression was
not altered.
CONCLUSION
High glucose-induced up-regulation and release of AM
from afferent arterioles and glomerular cells and active
filtration into urinary space possibly cause selective di-
latation of glomerular capillaries in STZ-induced dia-
betic Sprague-Dawley rat kidneys. The effect of AM
seems to be mediated by binding to its putative recep-
tor CRLR/RAMP2, and up-regulated glomerular expres-
sion of RAMP2 was also important in this process. Au-
tocrine and paracrine mode of action between AM and
AM receptor was also associated with the up-regulated
expression of ecNOS and enhanced nitric oxide release.
The protective role of AM against various tissue dam-
ages has been reported in lipopolysaccharide-induced
shock model in transgenic mice overexpressing AM in
the vasculature [55] and in STZ-induced diabetes animal
model in which adenovirus-mediated AM gene trans-
fer improves cardiac function and prevents renal dam-
ages. Thus, up-regulated renal expression of AM and
CRLR/RAPM2 may be adaptive and protective response
in acute hyperglycemia under the absolute deficiency of
insulin secretion. In later stages, glomerular hyperten-
sion induced by AM-nitric oxide system and persistent
hyperglycemia may lead to endothelial dysfunction (i.e.,
increase in ecNOS expression and oxidative stress and
decrease in AM and nitric oxide production via uncou-
pling mechanism, which may eventually lead to diabetic
glomerulosclerosis).
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